公开(公告)号：US20140275488A1

公开(公告)日：2014-09-18

申请号：US14204295

申请日：2014-03-11

申请人： PHARMABCINE INC.

发明人： Jin-San YOO ,  Weon-Sup Lee ,  Sang-Ryeol Shim ,  Mi-Hee Park ,  Jeong-Eun Kang ,  Do-Yun Kim ,  Joon-Chul Lee ,  Dong-Heon Lee ,  Too-Hyon Cho ,  Sam-Sook Sul ,  Young-Guen Kwon ,  Bo-Jeong Pyun ,  Kwi-Hwa Kim ,  Chae-Ok Yun ,  Nahm-Ju Kim ,  Jae-Won Jeon ,  Dong-Sup Lee ,  Young-Woo Park ,  Geun-Bae Rha ,  Hyun-Sook Jang ,  Hyeon-Mi Yoo ,  Sung-Woo Kim ,  Semi Kim ,  Sang-Seok Koh

IPC分类号： C07K16/28

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/574

摘要： The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

公开(公告)号：US09249219B2

公开(公告)日：2016-02-02

申请号：US14204295

申请日：2014-03-11

申请人： PHARMABCINE INC.

发明人： Jin-San Yoo ,  Weon-Sup Lee ,  Sang-Ryeol Shim ,  Mi-Hee Park ,  Jeong-Eun Kang ,  Do-Yun Kim ,  Joon-Chul Lee ,  Dong-Heon Lee ,  Too-Hyon Cho ,  Sam-Sook Sul ,  Young-Guen Kwon ,  Bo-Jeong Pyun ,  Kwi-Hwa Kim ,  Chae-Ok Yun ,  Nahm-Ju Kim ,  Jae-Won Jeon ,  Dong-Sup Lee ,  Young-Woo Park ,  Geun-Bae Rha ,  Hyun-Sook Jang ,  Hyeon-Mi Yoo ,  Sung-Woo Kim ,  Semi Kim ,  Sang-Seok Koh

IPC分类号： C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574 ,  A61K39/00

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/574

摘要： The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

公开(公告)号：US09249220B2

公开(公告)日：2016-02-02

申请号：US14204309

申请日：2014-03-11

申请人： PHARMABCINE INC.

发明人： Jin-San Yoo ,  Weon-Sup Lee ,  Sang-Ryeol Shim ,  Mi-Hee Park ,  Jeong-Eun Kang ,  Do-Yun Kim ,  Joon-Chul Lee ,  Dong-Heon Lee ,  Too-Hyon Cho ,  Sam-Sook Sul ,  Young-Guen Kwon ,  Bo-Jeong Pyun ,  Kwi-Hwa Kim ,  Chae-Ok Yun ,  Nahm-Ju Kim ,  Jae-Won Jeon ,  Dong-Sup Lee ,  Young-Woo Park ,  Geun-Bae Rha ,  Hyun-Sook Jang ,  Hyeon-Mi Yoo ,  Sung-Woo Kim ,  Semi Kim ,  Sang-Seok Koh

IPC分类号： C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574 ,  A61K39/00

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/574

摘要： The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

公开(公告)号：US20140288274A1

公开(公告)日：2014-09-25

申请号：US14204309

申请日：2014-03-11

申请人： PHARMABCINE INC.

发明人： Jin-San Yoo ,  Weon-Sup Lee ,  Sang-Ryeol Shim ,  Mi-Hee Park ,  Jeong-Eun Kang ,  Do-Yun Kim ,  Joon-Chul Lee ,  Dong-Heon Lee ,  Too-Hyon Cho ,  Sam-Sook Sul ,  Young-Guen Kwon ,  Bo-Jeong Pyun ,  Kwi-Hwa Kim ,  Chae-Ok Yun ,  Nahm-Ju Kim ,  Jae-Won Jeon ,  Dong-Sup Lee ,  Young-Woo Park ,  Geun-Bae Rha ,  Hyun-Sook Jang ,  Hyeon-Mi Yoo ,  Sung-Woo Kim ,  Semi Kim ,  Sang-Seok Koh

IPC分类号： C07K16/28

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/574

摘要： The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

摘要翻译： 本发明涉及中和血管内皮生长因子受体的人单克隆抗体及其用途。 更具体地，涉及中和血管内皮生长因子受体的人ScFv分子，以及含有人ScFv分子的抑制血管生成的组合物和治疗癌症的组合物。 与市售的针对血管内皮生长因子受体的抗体相比，公开的单克隆抗体中和血管内皮生长因子受体显示出优异的活细胞中和能力，并且显示出不仅在人体中中和血管内皮生长因子受体的能力，而且 也在老鼠和老鼠。 因此，单克隆抗体可用于抗癌研究，并且在癌症治疗中将是非常有效的。